NCT03225547: Study of Pembrolizumab and Mifepristone in Patients With Advanced HER2-negative Breast Cancer

NCT03225547
Breast Cancer Type: HR+ & HER2-negative, Triple Negative
Hormone Mutations: ER+
Other Mutations: 
Breast Cancer Tissue: 
Recruitment Status: Recruiting
Phase 2
Drug Category: Immunotherapy, Therapeutic Antibody, Endocrine (Hormone) Therapy

Key Eligibility Criteria:

Gender: All
Age: 18 Years and older (Adult, Senior)
Location of Metastases: 
Additional Notes: If HR+/HER2-negative, must also be ER+
Exclusions: Known active central nervous system (CNS) metastases- see trial for details
https://ClinicalTrials.gov/show/NCT03225547

Comments are closed.

Up ↑